Primary immunodeficiency disorders result from genetic defects in immune-cell development or function. Manifestations range from recurrent infections (antibody deficiencies) to autoimmunity and malignancy (cellular deficiencies). Treatment is individualised and may include immunoglobulin replacement, prophylactic antibiotics, or stem-cell transplantation.
Intravenous immunoglobulin (IVIG) replacement compensates for antibody deficiency in hypogammaglobulinaemia and common variable immunodeficiency (CVID), reducing infection rates by 70–90%. Subcutaneous immunoglobulin (SCIg) allows home-based infusions. Prophylactic antibiotics (trimethoprim-sulphamethoxazole, azithromycin) prevent opportunistic infections in combined immunodeficiencies. Hematopoietic stem-cell transplantation (HSCT) is curative for severe combined immunodeficiency (SCID), adenosine deaminase deficiency, and other cellular defects when a matched donor is available. Gene therapy—ex-vivo correction of patient-derived haematopoietic stem cells—has achieved remission in SCID-ADA and is under investigation for other disorders. Enzyme-replacement therapy (ADA-PEG) provides temporary improvement in ADA-SCID.
High-dose vitamin D and micronutrient supplementation (zinc, selenium, vitamin C) support immune function in borderline deficiency but cannot replace immunoglobulin or cellular therapy. Herbal immune support (astragalus, echinacea, elderberry) is used anecdotally but lacks evidence in primary disorders. Stress reduction and sleep optimisation support immune homeostasis.
Haematopoietic stem-cell transplantation and gene therapy are established regenerative approaches for primary immunodeficiency. Ex-vivo lentiviral gene correction of patient-derived HSCs is being studied for IL2RG-SCID, ADA-SCID, and adenylate-kinase deficiency. Mesenchymal stem cells are under investigation for immune tolerance induction in autoimmune-predominant phenotypes. Review candidacy criteria and specialist referral.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Intravenous immunoglobulin (IVIG) replacement | Standard | Strong | €15,000–40,000/year | Low | None (ongoing) |
| Subcutaneous immunoglobulin (SCIg) | Standard | Strong | €12,000–35,000/year | Low | None (ongoing) |
| Prophylactic antibiotic (TMP-SMX, azithromycin) | Standard | Strong | €300–800/year | Low | None |
| Haematopoietic stem-cell transplantation (HSCT) | Standard | Strong | €100,000–200,000 | High | 8–12 weeks |
| Gene therapy (lentiviral HSC correction) | Standard | Moderate | €200,000–400,000 | High | 8–16 weeks |
| Vitamin D + micronutrient optimisation | Alternative | Moderate | €200–500/year | Low | None |
| Immune-tolerance mesenchymal stem cells | Regenerative | Investigational | €18,000–35,000 (trial-dependent) | Medium | 2–4 weeks |
No. Primary immunodeficiency is a genetic disorder causing poor immune function. Immunosuppression is acquired (from medication or disease) and may be reversible.
Gene therapy using ex-vivo corrected haematopoietic stem cells has achieved curative outcomes in SCID-ADA and IL2RG-SCID. It is not yet available for all disorders but represents a major advance.
Frequency depends on baseline immunoglobulin levels and infection rate. Most patients receive IVIG every 3–4 weeks intravenously or weekly via subcutaneous infusion.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية